RBC Capital Reaffirms Their Hold Rating on McKesson (MCK)
RBC Capital analyst Ryan Halsted maintained a Hold rating on McKesson (MCK) with a $845 price target. McKesson has a Strong Buy consensus and $987.75 average price target. Q2 revenue was $105.38B, down from $97.83B last year, with net profit decreasing from $784M to $614M. Insider sentiment is negative, with increased selling activity.
How this was made
The 30-second read
Why it matters
The reaffirmation does not change the investment thesis; earnings showed revenue growth but a decline in net profit, and insider selling was modest.
Market read
The article provides a brief analyst rating update and recaps already‑published earnings, offering limited new trading insight.
What to watch
Potential cost‑cutting initiatives or upcoming contract wins not discussed in the article.
Background
RBC Capital analyst Ryan Halsted reaffirmed a Hold rating on McKesson, citing the company's recent quarterly earnings and insider activity.
Ticker impact
RBC Capital reaffirmed a Hold rating on McKesson and cited the latest earnings release and recent insider sales.
Limited short‑term move; price may stay range‑bound around current levels.
The rating is unchanged and the price target is modest; earnings numbers are already public, and insider sales are small, offering little actionable edge.
Market effects
Healthcare distribution sector sees modest revenue growth but profit pressure, no major sector shift.
U.S. market impact minimal; McKesson is a large cap but rating unchanged.
Limited global relevance; focus remains on U.S. investors.
Counterpoint
If investors expect a turnaround in profit margins, the hold rating may be too conservative.
Key entities
- CompanyMcKesson
U.S. healthcare services and pharmaceutical distribution company.
- Research FirmRBC Capital
Equity research analyst firm providing the Hold rating.
